Andrew J. Sims
Net Worth

Last updated:

What is Andrew J. Sims net worth?

The estimated net worth of Mr. Andrew J. Sims is at least $1,509,311 as of 8 May 2024. He owns shares worth $2,951 as insider and has received compensation worth at least $1,506,360 in Plus Therapeutics, Inc..

What is the salary of Andrew J. Sims?

Mr. Andrew J. Sims salary is $376,590 per year as Vice President of Fin. & Chief Financial Officer in Plus Therapeutics, Inc..

How old is Andrew J. Sims?

Mr. Andrew J. Sims is 52 years old, born in 1973.

What stocks does Andrew J. Sims currently own?

As insider, Mr. Andrew J. Sims owns shares in one company:

Company Title Shares Price per share Total value
Plus Therapeutics, Inc. (PSTV) Vice President of Fin. & Chief Financial Officer 5,717 $0.52 $2,951

What does Plus Therapeutics, Inc. do?

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Andrew J. Sims insider trading

Plus Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 4,902 $2.04 $10,000
Purchase
Common Stock 3,000 $0.67 $2,016
Purchase
Common Stock 2,000 $1.1 $2,200
Purchase
Common Stock 1,000 $1.86 $1,864
Purchase
Common Stock 2,000 $1.67 $3,338
Purchase
Common Stock 2,244 $1.91 $4,286
Purchase
Common Stock 1,986 $2.05 $4,071

Plus Therapeutics key executives

Plus Therapeutics, Inc. executives and other stock owners filed with the SEC: